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Abstract
Background: Highly active anti-retroviral therapy (HAART) is the current HIV/AIDS treatment modality.
Despite the fact that HAART is very effective in suppressing HIV-1 replication and reducing the mortality
of HIV/AIDS patients, it has become increasingly clear that HAART does not offer an ultimate cure to HIV/
AIDS. The high cost of the HAART regimen has impeded its delivery to over 90% of the HIV/AIDS
population in the world. This reality has urgently called for the need to develop inexpensive alternative
anti-HIV/AIDS therapy. This need has further manifested by recent clinical trial failures in anti-HIV-1
vaccines and microbicides. In the current study, we characterized a panel of extracts of traditional Chinese
medicinal herbal plants for their activities against HIV-1 replication.
Methods: Crude and fractionated extracts were prepared from various parts of nine traditional Chinese
medicinal herbal plants in Hainan Island, China. These extracts were first screened for their anti-HIV
activity and cytotoxicity in human CD4+ Jurkat cells. Then, a single-round pseudotyped HIV-luciferase
reporter virus system (HIV-Luc) was used to identify potential anti-HIV mechanisms of these extracts.
Results:  Two extracts, one from Euphorbiaceae,  Trigonostema xyphophylloides (TXE) and one from
Dipterocarpaceae, Vatica astrotricha (VAD) inhibited HIV-1 replication and syncytia formation in CD4+
Jurkat cells, and had little adverse effects on host cell proliferation and survival. TXE and VAD did not show
any direct inhibitory effects on the HIV-1 RT enzymatic activity. Treatment of these two extracts during
the infection significantly blocked infection of the reporter virus. However, pre-treatment of the reporter
virus with the extracts and treatment of the extracts post-infection had little effects on the infectivity or
gene expression of the reporter virus.
Conclusion: These results demonstrate that TXE and VAD inhibit HIV-1 replication likely by blocking
HIV-1 interaction with target cells, i.e., the interaction between gp120 and CD4/CCR5 or gp120 and CD4/
CXCR4 and point to the potential of developing these two extracts to be HIV-1 entry inhibitors.
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Background
Human immunodeficiency virus type 1 (HIV-1) causes
acquired immune deficiency syndrome (AIDS) [1,2].
CD4+ T lymphocytes are the natural target of HIV-1 infec-
tion [3]. At the cellular level, HIV-1 life cycle begins with
binding of HIV-1 gp120 to cellular receptors CD4 and
chemokine receptors CCR5 or CXCR4 that are expressed
on the surface of HIV-1 target cells, followed by gp41 con-
formational change, which in turn leads to virus-cell
membrane fusion and entry of the viral core (nucleocap-
sid) into the cytoplasm [4-6]. The virion core undergoes
uncoating, the viral RNA genome is converted into provi-
ral DNA by the virally encoded enzyme reverse tran-
scriptase (RT) [7]. The DNA enters the nucleus and is
covalently integrated into the genome of the host cell by
the second virally encoded enzyme integrase (IN) [8-10].
The integrated viral DNA serves as the template for viral
transcription and synthesis of various components of
progeny viruses [7]. Progeny viruses are assembled on and
budded through the plasma [11,12]. As a result, the prog-
eny viruses become encapsulated by a layer of membrane
that also harbors the viral envelope glycoproteins [6].
Concomitant with budding, a third virally encoded
enzyme protease (PR) processes the core proteins into
their final forms, and the virion undergoes a morphologic
change known as maturation [7,13]. This final step primes
the progeny viruses for the next round of infection.
In parallel with these progresses made in our understand-
ing of basic HIV-1 virology and pathogenesis is develop-
ment of anti-HIV-1 therapeutics. The primary targets for
anti-HIV-1 therapeutic development have been two virally
encoded enzymes: RT and PR. The Food and Drug Admin-
istration (FDA) has approved a total of 21 anti-HIV-1
drugs, a majority of these drugs are HIV-1 RT and PR
inhibitors. Various combinations of these inhibitors, so-
called highly active anti-retroviral therapy (HAART) is
very effective in suppressing viral replication and has led
to a significant reduction in the mortality rate of the dis-
ease, increase in the lifespan of HIV/AIDS patients and
improvement of the quality of life of these patients [14-
16]. However, issues such as viral reservoirs, drug resist-
ance, high dosages and frequencies, and high cost, have
led to a significant crisis in the management of HIV/AIDS
patients, particularly in developing nations, where there is
the greatest need [17-19]. It has become evident that
HAART does not offer a complete solution to the prob-
lem. Meanwhile, relatively fewer anti-HIV-1 therapeutics
have been developed to target other steps of HIV-1 life
cycle including entry, fusion, and integration. On the
other hand, recent trials on anti-HIV-1 vaccines and
microbicides have shown that some of current vaccine
and microbicide strategies not only did not prevent but
actually increased HIV-1 infection and transmission risks
[20-23]. Therefore, additional and alternative anti-HIV-1
therapeutic strategies are desperately needed to be
explored and developed to fight this virus from destroying
the immune system of infected individuals and from
spreading the virus to others.
In the current study, we investigated a panel of traditional
Chinese medicinal herbal extracts obtained from plants in
Hainan Island, China, a geographically unique tropical/
subtropical region for their activities against HIV-1 repli-
cation. We demonstrate that extracts from Euphorbiaceae,
Trigonostema xyphophylloides (TXE) and Dipterocarpaceae,
Vatica astrotricha (VAD) both block HIV-1 replication at
the entry step. These results point to the potential of devel-
oping these plant extracts as anti-HIV-1 entry inhibitors.
Methods
Preparation of plant extracts
All plants used in this study were collected at national
tropical forest parks in Hainan island, the People's Repub-
lic of China (P.R. China) including Jianfengling, Bawan-
gling, or Mt. Diaoluo (Table 1). Scientific names and
classification of these plants were validated by Prof.
Qiongxin Zhong, a plant taxonomist at Department of
Biology Hainan Normal University, Haikou, P. R. China.
Samples of these plants were kept at the Hainan Provin-
Table 1: Tropical plants selected to make extracts for anti-HIV screening
Plant (family, species) Sampling location Sampling parts Medicinal usage
Euphorbiaceae, Antidesma ghaesembilla Mt. Diaoluo Stem Vascuodilation
Euphorbiaceae, Alchoornea rugosa Jianfengling Stem Rash
Euphorbiaceae, Alchoornea rugosa Jianfengling Leaves Rash
Euphorbiaceae, Trigonostema xyphophylloides Jianfengling Stem Asthma
Euphorbiaceae, Trigonostema xyphophylloides Jianfengling Leaves Asthma
Euphorbiaceae, Mallotus furetianus Mt. Diaoluo Stem Fever
Euphorbiaceae, Mallotus furetianus Mt. Diaoluo Leaves Fever
Euphorbiaceae, Sapium insigne Benth. Et Hook Bawangling Leaves Snake bite
Clavicipitaceae, Cordyceps inensis Sacc Haikou city Root TB, cough, sweating
Rubiaceae, Saprosma hainanense Merr Bawangling Stem Bactericidal
Guttiferae, Calophyllum membranaceum Bawangling Stem Arthritis, pain
Dipterocarpaceae, Vatica astrotricha Bawangling Leaves Bactericidal, hepatitis
Dipterocarpaceae, Vatica astrotricha Bawangling Stem Bactericidal, hepatitisBMC Complementary and Alternative Medicine 2009, 9:29 http://www.biomedcentral.com/1472-6882/9/29
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cial Key Laboratory of Tropical Pharmaceutical Herbal
Chemistry, Haikou, P. R. China. Plant samples were first
air dried, grinded and continued to be dried in a pressu-
rized oven at 40°C and 0.08 MPa. The dried and grinded
materials were then subjected to 3 rounds of refluxing
extraction in 75% ethanol at 80°C. The ethanol extracts
were then concentrated to become ointment in a revolv-
ing depressurized vacuum evaporator at 55°C. The oint-
ment was further lyophilized to the final form of powder
and stored at a desiccator. The powders were dissolved in
dimethyl sulfoxide (DMSO) at a concentration of 100
mg/ml with gentle shaking overnight at room tempera-
ture. Then, the mixtures were removed of any remaining
undissolved substances by centrifugation at 3,000 rpm for
10 min followed by filtration through a 0.4 μm syringe fil-
ter. The cleared ones were used in all experiments.
Cells, HIV-1 HXBc2 viruses and chemicals
Jurkat cells were purchased from American Tissue Culture
Collection (ATCC, Manassas, VA) and cultured in RPMI
1640 medium supplemented with 10% fetal bovine
serum, 100 units/ml penicillin, and 100 μg/ml streptomy-
cin sulfate. U87.CD4.CXCR4 and U87.CD4.CCR5 cells
expressing CD4/CXCR4 and CD4/CCR5 respectively were
obtained from the NIH AIDS Reagent Program [24] and
cultured in DMEM medium supplemented with 10% fetal
bovine serum, 100 units/ml penicillin, and 100 μg/ml
streptomycin sulfate. Proviral DNA of T-tropic HIV-1
strain HXBc2 was transfected into Jurkat cells to generate
viral inoculums by the DEAE-Dextran method. HIV-1
HXBc2 expresses HIV-1 Eli strain nef and all other HXB2
genes. Unless stated otherwise, all chemicals were from
Sigma (St. Louis, MO).
HIV-1 replication assay
One million Jurkat cells in 1 ml culture medium were
infected with HIV-1 corresponding to a 10,000 cpm RT
activity. At twenty-four hr post-infection, cells were
treated with plant extracts at indicated concentrations or
equivalent concentrations of the DMSO solvent. Fresh
extracts as well as DMSO were added every other day.
Meanwhile, the culture supernatants were collected for
the RT activity assay. Briefly, 1 ml of the culture superna-
tant was collected and cleared to remove any cells and cell
debris by centrifugation at 1,000 g for 5 min, followed by
filtration of the cleared supernatants through a 0.2 μm
syringe filter. Virions in the supernatant were pelleted by
centrifugation at 12,000 g for 1 hr and the RT activity was
determined as described [25,26].
Cytotoxicity and syncytia formation
The cytotoxicity of the plant extracts was determined
using the trypan blue exclusion method. Briefly, Jurkat
cells that were exposed to plant extracts in the presence or
absence of HIV-1 infection for various lengths of time
were stained in 0.2% trypan blue dye and then counted
for viable cells under a light microscope. HIV-1-infected
Jurkat cells were scored for syncytia formation from 4 ran-
dom fields from each of the triplicate samples over the
course of HIV-1 infection by a light microscope.
Preparation and infection of HIV-1 pseudotyped viruses
HIV-1 viruses pseudotyped with different envelope pro-
teins were prepared as previously described [27,28].
Briefly, 293T cells (2 × 106 cells per 10-cm plate) were
transfected with 20 μg of HIV-Luc plasmid and 4 μg of
pHXB2-env, p89.6-env, pVSV-G, or pcDNA3 by the cal-
cium phosphate precipitation method. Cell culture super-
natants were collected 48 hr after medium change,
filtered, and saved as virus stocks. For infection, pseudo-
typed viruses corresponding to a 2,000 cpm RT activity
were used to infect target cells. Following 2 hr infection,
the cells were removed of remaining viruses by multiple
washes with fresh medium. The cells were continued to
incubate for 48 hr and then harvested for the Luc activity
assay as described [27,28].
Fractionation of crude extracts of TXE and VAD
TXE and VAD extracts obtained above were suspended in
1.5 L H2O and partitioned successively with petroleum
ether (PE) (4 × 1.5 L), chloroform (CF) (5 × 1.5 L), ethyl
acetate (EA) (5 × 1.5 L), and n-butanol (BT) (5 × 1.5 L) to
obtain respective subfractions. The excessive solvents were
removed from these subfractions under a reduced pres-
sure to generate ointments. The ointments were lyophi-
lized to the powder form. These subfractions were
dissolved in DMSO at a concentration of 100 mg/ml by
overnight shaking on a shaker, and the undissolved mate-
rials were removed by low speed centrifugation followed
by filtration through syringe filter, as described above.
Data analysis
All values expressed as mean ± SEM, or representative of
at least three independent experiments. Comparisons
among groups were made using two-tailed Student's t-test.
A p value of < 0.05 was considered statistically significant
(*), and p < 0.01 highly significant (**).
Results
Anti-HIV-1 activity of extracts of traditional Chinese 
medicinal herbal plants
Traditional Chinese Medicine (TCM) dates back to 2000
to 3000 years. Medicinal herbs are a major component of
TCM. It is estimated that over 600 different herbs have
been used to treat various human diseases including those
caused by virus infection [29]. Hainan Island, the second
largest island off the coast of China, is located in the South
China Sea and in the tropics at about 18°N latitude. There
are about 4,200 plant species, 630 of which are listed as
endemic to the island and some are nearly extinct. In this
study, we selected 13 medicinal herbal plant parts that
have been used to treat various human diseases by localBMC Complementary and Alternative Medicine 2009, 9:29 http://www.biomedcentral.com/1472-6882/9/29
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ethnic Chinese in Hainan Island, China (Table 1),
extracted these plants with ethanol, and tested them for
the anti-HIV activity. We infected CD4+ T lymphocytes
Jurkat with a replication-competent T-tropic HIV-1 strain
HXB2 and then monitored HIV-1 replication over a
course of 2 weeks in the presence of the plant extracts at
concentrations of 1, 10, 100 μg/ml. We included the sol-
vent DMSO of the extracts and an HIV-1 RT inhibitor AZT
in these experiments. We repeated this initial testing three
times. Compared to the untreated control or DMSO treat-
ment, only two of these 13 extracts: one from the stem of
Euphorbiaceae, Trigonostema xyphophylloides (TXE) and the
other from the stem of Dipterocarpaceae, Vatica astrotricha
(VAD), displayed significant inhibition of HIV-1 replica-
tion at 10 μg/ml or higher at day 9 post infection (dpi)
(Figure 1A). As expected, the treatment control AZT inhib-
ited HIV-1 replication. These two extracts at 1 μg/ml and
all other extracts showed little effects on HIV-1 replication
but dose-dependent anti-HIV activity at 10 μg/ml or
higher. We also monitored cell survival of all treatments
throughout the experiments by trypan blue dye staining.
Compared to the untreated control, both TXE and VAD
treatments showed cell growth kinetics similarly to that of
DMSO and no treatment controls (Figure 1B). The decline
in the number of viable cells in HIV-1-infected cells likely
results from the infection-induced cell death, as the cell
number began to recover from AZT treatment toward the
end of the treatment. These results provide initial evi-
dence that TXE and VAD are inhibitory to HIV-1 replica-
tion.
Cytotoxicity of the extracts
To ascertain and establish non-toxic working concentra-
tions of the extracts, we further determined effects of these
extracts on cell survival and growth kinetics in the absence
of HIV-1 infection. We treated Jurkat cells with TXE or
VAD at 1, 10 and 100 μg/ml and added the fresh extract
every other day and monitored cell survival and growth.
We included DMSO and AZT as controls in these experi-
ments. Jurkat cells without any treatment were also
included as a control. The cell survival and growth kinetics
appeared to be indistinguishable among the cells receiv-
ing no treatment, AZT (10 μM), and 10 μg/ml TXE and
VAD and its corresponding DMSO concentration, i.e.,
0.1% (Figure 2). Similar results were obtained between
TXE and VAD at 1 and 100 μg/ml and their respective sol-
vent DMSO concentrations 1% and 0.01% (data not
shown), suggesting that TXE and VAD are not toxic at a
concentration up to 100 μg/ml. Based on these results, we
chose the concentration of 10 μg/ml for TXE and VAD
extracts for all following mechanistic studies.
Inhibition of HIV-1-induced syncytia formation by the 
extracts
Productive HIV-1 infection of CD4+ T cells in vitro is char-
acterized by formation of multinucleated giant cells, so-
called syncytia, which likely results in CD4+ T cell deple-
tion in HIV-1-infected subjects. We next determined
effects of these two extracts on syncytia formation. We
infected Jurkat cells, treated them with 10 μg/ml TXE or
VAD, and monitored the syncytia formation in these cells
over a course of 2 weeks. We also included AZT (5 μM)
and DMSO (0.1%) as controls. In addition, we also had
uninfected and HIV-1-infected Jurkat cells as controls. The
number of syncytia reached the highest at day 7 post infec-
tion. Compared to untreated and DMSO-treated HIV-1-
infected Jurkat cells, TXE, VAD and AZT treatments all
showed significant reduction (Figure 3). There were few
syncytia in Jurkat cells that received no HIV-1-infection.
These results are in agreement with the inhibitory effects
of these extracts on HIV-1 replication (Figure 1A).
No inhibition of HIV-1 RT activity by the extracts
HIV-1 is a member of the retrovirus family. The most
important feature of these viruses is that replication of
these viruses involves conversion of their RNA viral
genome to proviral DNA, which is catalyzed by a unique
virally encoded enzyme called reverse transcriptase (RT).
Therefore, we next determined whether the extracts
directly inhibited HIV-1 RT enzymatic activity. To do so,
we compared the RT enzymatic activity of HIV-1 virions in
the presence and absence of the extracts. We lysed HIV-1
virions to release the RT and performed the RT activity
assay in the presence of TXE and VAD (10 μg/ml). We also
included the RT inhibitor AZT (5 μM) as a control in these
experiments. In addition, we also included PBS and
DMSO (0.1%) as the solvent controls for AZT and TXE
and VAD, respectively. The RT reaction without any HIV-
1 virions was used as an assay blank control. As expected,
AZT potently inhibited HIV-1 RT activity. However, inclu-
sion of TXE and VAD in the RT reaction did not show any
significance difference in the RT activity from the PBS and
DMSO control (Figure 4). These results imply that TXE
and VAD-induced inhibition of HIV-1 replication is not
due to their effects on the RT activity but on other steps of
HIV life cycle.
Block of HIV-1 entry by these extracts
HIV-1 infection begins with HIV-1 envelope gp120 bind-
ing to CD4 and chemokine co-receptors CCR5 (for M-
tropic strains) or CXCR4 (for T-tropic strains) on the cell
surface of HIV-1 target cells. Thus, we next determined
whether the extracts had any effects on HIV-1 entry. To
achieve this, we took advantage of the replication-defec-
tive single round HIV-Luc reporter system [30]. The repli-
cation-defective HIV-Luc reporter system has the HIV-1
env gene inactivated and the firefly luciferase (Luc) gene in
place of HIV-1 nef. Such a design allows in trans comple-
mentation of any viral envelope proteins including HIV-1
envelope proteins and one single round viral infection to
accurately determine HIV-1 entry by the sensitive Luc
activity assay. We prepared HIV-Luc reporter viruses pseu-BMC Complementary and Alternative Medicine 2009, 9:29 http://www.biomedcentral.com/1472-6882/9/29
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Effects of the extracts from TXE and VAD on HIV replication and cell survival Figure 1
Effects of the extracts from TXE and VAD on HIV replication and cell survival. Jurkat cells were infected with HIV-
1 HXB2 and then exposed to the extracts 24 hr post infection. Fresh extracts were added every other day. Meanwhile, culture 
supernatants were collected for the RT activity assay (A), and aliquots of cells were stained with trypan blue dye and counted 
for viable cells (B). DMSO was the solvent of the extracts and included as a negative control, while AZT was included as a pos-
itive control. In addition, Jurkat cells without HIV infection [Ctrl, (-HIV)] and Jurkat cells with HIV infection but without any 
treatments [Ctrl, (+HIV)] were also included. These data were representative of three independent experiments.BMC Complementary and Alternative Medicine 2009, 9:29 http://www.biomedcentral.com/1472-6882/9/29
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dotyped with T-tropic HIV-1 HXB2 envelope. To deter-
mine effects of these extracts on HIV-1 entry, we pre-
incubated U87.CD4.CXCR4 cells with these extracts at 10
μg/ml and then infected these cells with these viruses. We
then determined the Luc activity of these cells. We also
prepared HIV-Luc reporter viruses pseudotyped with vas-
cular stomatitis virus envelope glycoprotein (VSV-G) or
HIV-Luc viruses without any viral envelopes, which were
positive and negative controls, respectively, in these exper-
iments. We also included DMSO (0.1%) as the solvent
control for these extracts. Compared to the DMSO con-
trol, pre-incubation of U87.CD4.CXCR4 with TXE almost
completely blocked infection of HIV-Luc pseudotyped
with HIV-1 HXB2 envelope but had no effects on that of
HIV-Luc pseudotyped with VSV-G (Figure 5A). Similar
results were obtained with VAD extract (Figure 5B). These
results led us to conclude that TXE and VAD inhibited
HIV-1 replication through their block in HIV-1 entry to
target cells.
No effects of the extracts on HIV-1 itself and HIV-1 post-
entry
To further ascertain that TXE and VAD inhibited HIV-1
replication at the entry step and to determine whether TXE
and VAD directly inactivated HIV-1 and had any effects at
other steps of HIV-1 life cycle, we took advantage of the
same replication-defective single round HIV-Luc reporter
system but with a modified experimental scheme. We first
incubated the same amount of HIV-Luc viruses pseudo-
typed with HXB2 envelope in 10 μg/ml TXE, VAD, or
0.1% DMSO at 37°C for 2 hr. We then recovered the
viruses by centrifugation and used them to infect
U87.CD4.CXCR4 cells. We cultured the cells for 48 hr
before we harvested them for the Luc activity assay. The
Luc activity showed no significant difference in the viral
Effects of the extracts on cell proliferation and survival Figure 2
Effects of the extracts on cell proliferation and sur-
vival. Jurkat cells were exposed to the extracts for various 
lengths of time as indicated. Fresh extracts were added every 
other day. Cells without any treatments, treated with 
DMSO, or AZT were included as controls. Viable cells were 
determined using the trypan blue dye staining. These data 
were representative of three independent experiments.
Effect of the extracts on syncytia formation in HIV-1-infected  Jurkat cells Figure 3
Effect of the extracts on syncytia formation in HIV-1-
infected Jurkat cells. Jurkat cells were infected with HIV-1 
and then exposed to the extracts at 10 μg/ml, 0.1% DMSO, 
or 5 μM AZT. Syncytia in each of these treatments were 
counted from 4 random fields from each one of the triplicate 
samples under a light microscope over the course of 2 weeks 
infection. The data represented the number of syncytia at day 
7 post infection when the maximal number of syncytia was 
recorded in the infections receiving no treatments (None) or 
DMSO. Jurkat cells without HIV-1 infection were included as 
a control (Mock). The data were mean ± SEM of triplicate 
experiments.
Direct effects of the extracts on the RT activity Figure 4
Direct effects of the extracts on the RT activity. HIV-1 
virions were assayed for their RT activity in the presence of 
the extracts at 10 μg/ml. AZT-TP (5 μM) was included as a 
positive control. DMSO (0.1%) and phosphate-buffered saline 
(PBS) were included as the solvent control for the extracts 
and AZT, respectively. The RT reaction without any input 
HIV-1 virions was also included as an assay control. The data 
were mean ± SEM of triplicate experiments.BMC Complementary and Alternative Medicine 2009, 9:29 http://www.biomedcentral.com/1472-6882/9/29
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infectivity between DMSO treatment control and TXE or
VAD treatment, while heat-inactivated viruses had little
infectivity (Figure 6A). Next, we first infected
U87.CD4.CXCR4 cells with HIV-Luc viruses pseudotyped
with HIV-1 HXB2 envelope at 37°C for 2 hr. We then
removed the remaining input viruses by repeated washes
with fresh medium and cultured these cells for 48 hr in
the presence of these extracts (10 μg/ml) or 5 μM AZT. We
then harvested the cells for the Luc activity assay. Com-
pared to the AZT control, TXE and VAD treatment did not
show any differences in the Luc activity of HIV-infected
cells from the DMSO treatment (Figure 6B). Taken
together, these results show that the observed inhibition
of TRX and VAD on HIV-1 replication is not due to inacti-
vation of HIV-1 by these extracts or the blockage at the
post-entry step, further supporting our conclusion that
TRE and VAD inhibit HIV-1 replication at the entry step of
the viral life cycle.
Effect of TXE or VAD on entry of primary HIV-1 isolate 
89.6 into cells
Next, we extended our experiments to the dual tropic pri-
mary HIV-1 isolate 89.6 [31] to investigate whether TXE
and VAD were also capable of blocking this virus from
entering into its target cells. To this end, we treated
U87.CD4.CXCR4 and U87.CD4.CCR5 cells were treated
with10 μg/ml of TXE or VAD, and then infected the cells
with HIV-Luc viruses pseudotyped with HIV-1 89.6 enve-
lope and performed the Luc activity assay. Compared to
the DMSO treatment control, both TXE and VAD treat-
ment showed significant lower Luc activities in both
U87.CD4.CXCR4 and U87.CD4.CCR5 cells (Figure 7A),
indicating that they blocked HIV-1 89.6 infection. In addi-
tion, we also determined effects of the extracts on HIV-1
89.6 itself and at the post-entry step. Similarly to HXB2
viruses, 89.6 viruses did not show any changes in their
infectivity when they were exposed to the extracts prior to
the infection (Figure 7B) and in their post-entry replica-
tion when 89.6 infection occurred prior to the extract
treatment (Figure 7C). Furthermore, these extracts did not
have any direct inhibitory effects on the RT enzymatic
activity of the HIV-1 89.6 viruses (Figure 7D). Taken
together, these data demonstrate that TXE and VAD both
also possessed the similar activity to block entry of pri-
mary HIV-1 isolate 89.6.
Identification of anti-HIV components of TXE and VAD
As part of further characterization of the anti-HIV activity
of these two crude extracts, we next partitioned them into
four subfractions using organic solvents of different
hydrophobicity and polarity, that is, petroleum ether
(PE), chloroform (CF), ethyl acetate (EA) and n-butanol
(BT). We then determined the effects of these subfractions
on HIV-1 replication. As showed above, TXE treatment
Effects of the extracts on HIV-1 entry Figure 5
Effects of the extracts on HIV-1 entry. U87.CD4.CXCR4 cells were treated with TXE (A) or VAD (B) at a concentration 
of 10 μg/ml for 30 min and then infected with HIV-Luc viruses pseudotyped T-tropic HIV-1 HXB2 envelope (HXB2) or without 
envelope (-) for 2 hr. Forty-eight hours post infection, cells were harvested for the Luc activity assay. HIV-Luc viruses pseudo-
typed with VSV-G envelope (VSV-G) were included as a control. DMSO (0.1%) was also included as a solvent control for the 
extracts. The data were mean ± SEM of triplicate experiments.BMC Complementary and Alternative Medicine 2009, 9:29 http://www.biomedcentral.com/1472-6882/9/29
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inhibited HIV-1 replication in a highly significant fashion
(Figure 8A). Compared to the DMSO-treated control, HIV
replication was significantly lower in cells treated with CF
and BU subfractions, while HIV replication showed little
changes in cells treated with its PE and EA subfractions. In
contrast, the PE, CF, and EA subfractions of the VAD
extract had highly significantly lower HIV-1 replication
than the DMSO control, while its BT subfraction dis-
played no anti-HIV activity (Figure 8B). Similar results
were obtained from the single-round infection assay (data
not shown). These results suggest that the active anti-HIV
components can be further isolated from both TXE and
VAD extracts and may differ between these two extracts.
Discussion
Using a well-established HIV-1 replication system, we
screened extracts of traditional Chinese medicinal herbal
plants for their anti-HIV activities (Table 1). We showed
that extracts from the stem of Euphorbiaceae, Trigonostema
xyphophylloides  (TXE) and the stem of Dipterocarpaceae,
Vatica astrotricha (VAD) inhibited HIV-1 replication with-
out apparent effects on cell proliferation and cell survival
(Figure 1 and Figure 2). The inhibitory effects of these two
extracts were further corroborated by the finding that
these extracts prevented HIV-infected cells from forming
syncytia (Figure 3). Nevertheless, we did not detect any
effects of these extracts on HIV-1 RT enzymatic activity
(Figure 4). Instead, we showed that these extracts potently
blocked HIV-1 from entering its target cells (Figure 5).
Furthermore, we showed that these extracts had little
effects on post-entry HIV-1 gene expression (Figure 6). We
obtained similar results with the primary isolate, HIV-1
89.6 which displays dual tropism, using both CXCR4 and
CCR5 for entry into cells (Figure 7). Taken together, these
studies revealed the anti-HIV activities of these two plant
extracts and suggest that their anti-HIV activity results
from interfering with HIV-1 entry.
All currently FDA-approved anti-HIV drugs are chemically
synthesized [32,33]. Development of these drugs involves
an extremely long cycle of research, design and optimiza-
tion, thus these drugs are very expensive. Besides, as many
of these drugs are structural analogs of host metabolic
components, use of these drugs is often limited by side-
effects and non-adherence issues. In contrast, medicines
of natural origins such as herbs have a much short devel-
opment cycle and relatively inexpensive. Importantly, the
toxicity of nature-derived medications is rarely an issue. A
recent study has shown that more than two third of those
who are on anti-HIV medications are also taking alterna-
tive therapy, including nearly 25% on those derived from
botanicals and Chinese herbs [34,35]. There is clearly a
need to further investigate and develop this alternative
anti-HIV therapy, as it likely makes the anti-HIV therapy
ultimately affordable and available to all HIV/AIDS-
affected individuals including those in developing and
under-developed countries.
Effects of the extracts on HIV-1 and HIV-1 gene expression Figure 6
Effects of the extracts on HIV-1 and HIV-1 gene expression. A. HIV-Luc viruses pseudotyped T-tropic HIV-1 HXB2 
envelope (HXB2) were incubated with 10 μg/ml extracts for 2 hr and then used to infect U87.CD4.CXCR4 cells. Cells were 
harvested 48 hr for the Luc activity assay 48 hr after infection. Infection with heat-inactivated HIV-Luc/HXB2 viruses (Δ Virus) 
was included as the control. B. U87.CD4.CXCR4 cells were infected with HIV-Luc viruses pseudotyped T-tropic HIV-1 HXB2 
envelope (HXB2) or without envelope (-) for 2 hr and then removed of the remaining input viruses by repeated washes with 
fresh medium. Then, the infected cells were cultured for 48 hr in the presence of the extracts (10 μg/ml) and then harvested 
for the Luc activity assay. DMSO (0.1%) was also included as a solvent control for the extracts, while 0.5 μM AZT was included 
as a positive control. The data were mean ± SEM of triplicate experiments.BMC Complementary and Alternative Medicine 2009, 9:29 http://www.biomedcentral.com/1472-6882/9/29
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Some efforts have been made to identify natural remedies
to combat HIV/AIDS in clinical settings. A number of nat-
ural products have been shown to possess anti-HIV-1
activities, including those derived from microorganisms,
marine organisms, and plants, and these natural products
inhibit HIV-1 replication at various steps of HIV-1 life
cycle [36]. Currently, more than 150 natural products
have been isolated from marine organisms to show prom-
ising anti-HIV-1 activity [37,38]. One of the outstanding
examples is cyanovirin-N, an 11 KDa anti-HIV-1 protein
that was initially isolated from the cyanobacterium (blue-
green alga) Nostoc ellipsosporum [39]. Cyanovirin-N inhib-
its HIV-1 replication through its vivid binding to HIV-1
gp120 and as a result, inactivates the viruses and blocks
the fusion of viruses to the cell membrane [40,41]. The
protein is now in Phase II clinical trial to be used as an
anti-HIV-1 microbicide.
Traditional Chinese Medicines (TCMs) have a very long
history. They have been used to treat various human dis-
eases and regarded as the state cultural treasure by the Chi-
nese government. Development and standardization of
TCMs have recently been proposed as the top biomedical
research priority for the next 5–10 years in P. R. China.
Studies on the anti-HIV activities and mechanisms of
TCMs are very limited and are expected to accelerate. Cur-
rently, HIV-1-inhibitory TCMs are reported to include
Scutellaria baicalensis Georgi, Prunella vulgaris, Paeonia
Suffruticosa, Rhizoma Polygoni Cuspidati, Radix Noto-
ginseng, Ramulus Visci, and Ajuga Decumbens Thumb
[42-47]. Our studies added Euphorbiaceae,  Trigonostema
xyphophylloides (TXE) and Dipterocarpaceae, Vatica astrot-
richa (VAD) onto this soon-to-be-rapidly-expanding list.
Studies are under way to further fractionate these extracts
for identification of the active anti-HIV-1 entry constitu-
Effects of the extracts on primary HIV-1 isolate 89.6 Figure 7
Effects of the extracts on primary HIV-1 isolate 89.6. A. U87.CD4.CXCR4 and U87.CD4.CCR5 cells were first treated 
with 10 μg/ml extracts and then infected with HIV-Luc viruses pseudotyped with 89.6 envelope. Infection of HIV-Luc viruses 
without an envelope was included as the mock infection control. B. HIV-Luc viruses pseudotyped 89.6 envelope were first 
incubated with 10 μg/ml extracts and then used to infect U87.CD4.CXCR4 and U87.CD4.CCR5 cells. Infection with heat-inac-
tivated HIV-Luc/89.6 viruses (Δ Virus) was included as the control. C. U87.CD4.CXCR4 and U87.CD4.CCR5 were first 
infected with HIV-Luc viruses pseudotyped with 89.6 envelope and then treated with 10 μg/ml extracts or 5 μM AZT. A-C: 
open bar for U87.CD4.CXCR4 cells; closed bar for U87.CD4.CCR5 cells. D. HIV-Luc viruses pseudotyped with 89.6 envelope 
were directly treated with 10 μg/ml extracts or 5 μM AZT-TP, the RT activity was determined. The data were mean ± SEM of 
triplicate experiments.BMC Complementary and Alternative Medicine 2009, 9:29 http://www.biomedcentral.com/1472-6882/9/29
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ents in these extracts and for better characterization of
their effects on the interaction between HIV-1 gp120 and
CD4/chomine receptors CCR5 and CXCR4.
Conclusion
TXE and VAD extracts possess potent inhibitory activities
against HIV-1 replication and entry of both T and M tropic
HIV-1 isolates. These results suggest that TXE and VAD are
potential biosources for further identification and isola-
tion of active anti-HIV-1 constituents. Identification of
these active constituents will help establish the precise
mechanisms of this entry inhibition as well as standardize
the extracts for potential clinical translation.
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